Therapy of solid Walker carcinosarcoma 256 with bleomycin after synchronization with hydroxyurea.
Rats with the solid Walker carcinosarcoma 256 were synchronized with hydroxyurea (6 x 50 mg/kg or 1 x 300 mg/kg body weight) and treated with bleomycin (32 mg/kg body weight) at different time points thereafter. Bleomycin clearly affects Walker carcinosarcoma cells at the G1/S boundary or in S-phase. The improvement in the results of bleomycin therapy after pretreatment with hydroxyurea can mainly be accounted for by the synchronization of the tumour cells.
D000818:Animals; D001761:Bleomycin / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006918:Hydroxyurea / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009368:Neoplasm Transplantation; D051381:Rats; D013997:Time Factors
D001761:Bleomycin; D006918:Hydroxyurea